Phase 1 results disclosed Monday indicate the company’s protein-degrading drug can affect a tough-to-reach target called ...

Mankind Pharma slipped 3.51% to Rs 2,444.25 after the company's consolidated net profit declined 10.71% to Rs 420.77 crore in Q4 FY25 as against Rs 471.24 crore posted in Q4 FY24. However, revenue ...

Several stocks experienced declines in today's trading session, with Colgate, Mankind Pharma, and BSE Limited leading the list of losers within the NIFTY MIDCAP 150. The movement highlights ...

Shares of Mankind Pharma dropped over 3 per cent on Thursday as the company reported a 10 per cent fall in consolidated net profit for the March quarter of 2024-25 (Q4 FY25). The Delhi-based pharma ...

On Thursday, JPMorgan (NYSE: JPM) analysts revised the price target for Mankind Pharma Ltd (MANKIND:IN), reducing it to INR2,900 from the previous INR3,150.Despite this adjustment, the firm retains an ...

On Thursday, JPMorgan analysts revised the price target for Mankind Pharma Ltd (MANKIND:IN), reducing it to INR2,900 from the previous INR3,150. Despite this adjustment, the firm retains an Overweight ...

On Thursday, BofA Securities analysts adjusted their outlook on Mankind Pharma Ltd (MANKIND:IN), lowering the price target to INR2,150 from INR2,250, while maintaining an Underperform rating on the ...

Mankind Pharma Limited announced its results for the quarter ended March 2025 and posted a mixed set of numbers. Though the business reported a robust topline, it was offset by a slip in profit ...